Charles River Laboratories International Company Profile (NYSE:CRL)

About Charles River Laboratories International

Charles River Laboratories International logoCharles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services. It has developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NYSE
  • Symbol: CRL
  • CUSIP: 15986410
Key Metrics:
  • Previous Close: $84.02
  • 50 Day Moving Average: $84.99
  • 200 Day Moving Average: $81.05
  • Trailing P/E Ratio: 28.39
  • Foreward P/E Ratio: 16.51
  • P/E Growth: 1.48
  • Market Cap: $3.97B
  • Outstanding Shares: 47,293,000
  • Beta: 1.29
Additional Links:
Companies Related to Charles River Laboratories International:

Analyst Ratings

Consensus Ratings for Charles River Laboratories International (NYSE:CRL) (?)
Ratings Breakdown: 2 Sell Ratings, 5 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $85.32 (1.55% upside)

Analysts' Ratings History for Charles River Laboratories International (NYSE:CRL)
Show:
DateFirmActionRatingPrice TargetDetails
8/4/2016Evercore ISIReiterated RatingHold$83.50 -> $91.50View Rating Details
8/4/2016Jefferies GroupBoost Price TargetBuy$94.00 -> $100.00View Rating Details
8/4/2016Citigroup Inc.Boost Price TargetNeutral$85.00 -> $90.00View Rating Details
6/20/2016Credit Suisse Group AGInitiated CoverageNeutral$84.00View Rating Details
5/22/2016KeyCorpReiterated RatingHold$77.00View Rating Details
5/20/2016Barclays PLCBoost Price TargetUnderweight$60.00 -> $65.00View Rating Details
4/26/2016GabelliInitiated CoverageBuy$96.00View Rating Details
2/11/2016Bank of America Corp.Reiterated RatingBuy$90.00 -> $87.00View Rating Details
2/11/2016Goldman Sachs Group Inc.Boost Price TargetSell$71.00 -> $74.00View Rating Details
2/11/2016Deutsche Bank AGReiterated RatingHold$85.00 -> $82.00View Rating Details
1/8/2016Robert W. BairdBoost Price TargetOutperform$86.00 -> $92.00View Rating Details
1/7/2016Wells Fargo & Co.UpgradeMarket Perform -> OutperformView Rating Details
8/28/2015William BlairReiterated RatingOutperformView Rating Details
7/10/2015Morgan StanleyReiterated RatingEqual Weight$65.00 -> $68.00View Rating Details
5/4/2015Edward JonesUpgradeNeutral -> BuyView Rating Details
5/4/2015SunTrust Banks Inc.UpgradeNeutral -> Buy$88.00View Rating Details
4/30/2015Cantor FitzgeraldReiterated RatingBuy$78.00View Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for Charles River Laboratories International (NYSE:CRL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/3/2016Q216$1.10$1.20$425.05 million$434.10 millionViewListenView Earnings Details
5/4/2016Q116$0.90$0.98$354.92 million$354.90 millionViewListenView Earnings Details
2/10/2016Q415$0.94$1.00$349.20 million$353.90 millionViewListenView Earnings Details
11/4/2015Q315$0.94$1.03$340.09 million$349.50 millionViewListenView Earnings Details
7/30/2015Q215$0.97$0.96$338.30 million$339.60 millionViewListenView Earnings Details
4/29/2015Q115$0.82$0.79$324.00 million$320.40 millionViewListenView Earnings Details
2/10/2015Q414$0.72$0.81$318.73 million$329.50 millionViewListenView Earnings Details
10/29/2014Q314$0.80$0.86$326.70 million$327.60 millionViewListenView Earnings Details
8/6/2014Q214$0.82$0.97$327.96 million$341.18 millionViewListenView Earnings Details
4/30/2014Q114$0.74$0.82$302.08 million$299.40 millionViewListenView Earnings Details
2/12/2014Q413$0.68$0.73$289.56 million$289.20 millionViewListenView Earnings Details
10/30/2013Q313$0.70$0.79$290.28 million$292.10 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.71$0.73$293.77 million$294.40 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.71$0.69$294.53 million$291.20 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.60$0.64$280.81 million$280.10 millionViewListenView Earnings Details
10/30/2012$0.62$0.65ViewN/AView Earnings Details
8/7/2012$0.66$0.75ViewN/AView Earnings Details
5/2/2012$0.65$0.70ViewN/AView Earnings Details
2/13/2012$0.56$0.69ViewN/AView Earnings Details
11/1/2011$0.58$0.57ViewN/AView Earnings Details
8/2/2011$0.60$0.70ViewN/AView Earnings Details
5/3/2011$0.55$0.61ViewN/AView Earnings Details
2/8/2011$0.50$0.60ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Charles River Laboratories International (NYSE:CRL)
Current Year EPS Consensus Estimate: $4.46 EPS
Next Year EPS Consensus Estimate: $5.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20169$0.84$0.95$0.91
Q2 20166$1.09$1.13$1.11
Q3 20165$1.12$1.14$1.14
Q4 20165$1.13$1.16$1.15
Q1 20173$1.07$1.19$1.14
Q2 20173$1.25$1.33$1.28
Q3 20172$1.28$1.32$1.30
Q4 20172$1.30$1.40$1.35
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Charles River Laboratories International (NYSE:CRL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Charles River Laboratories International (NYSE:CRL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/5/2016James C FosterChairmanSell18,351$85.63$1,571,396.13View SEC Filing  
7/29/2016Richard F WallmanDirectorSell7,740$88.00$681,120.00View SEC Filing  
7/1/2016George MassaroDirectorSell3,740$83.09$310,756.60View SEC Filing  
5/24/2016John J CrowleyCAOSell1,913$85.00$162,605.00View SEC Filing  
5/13/2016Richard F WallmanDirectorSell1,970$82.32$162,170.40View SEC Filing  
5/10/2016Richard F WallmanDirectorSell11,990$84.00$1,007,160.00View SEC Filing  
5/9/2016George MassaroDirectorSell985$82.17$80,937.45View SEC Filing  
5/6/2016Richard F WallmanDirectorSell2,720$81.00$220,320.00View SEC Filing  
4/6/2016Davide MolhoVPSell30,667$80.00$2,453,360.00View SEC Filing  
3/2/2016Nancy GillettVPSell7,015$75.00$526,125.00View SEC Filing  
2/29/2016Nancy GillettVPSell3,646$73.50$267,981.00View SEC Filing  
2/25/2016David P JohstVPSell34,075$73.02$2,488,156.50View SEC Filing  
2/24/2016James C FosterCEOSell3,873$70.40$272,659.20View SEC Filing  
2/23/2016George M Milne JrDirectorSell10,440$73.02$762,328.80View SEC Filing  
2/22/2016James C FosterCEOSell9,831$73.12$718,842.72View SEC Filing  
2/12/2016C Richard ReeseDirectorSell4,228$71.48$302,217.44View SEC Filing  
2/12/2016Nancy GillettVPSell6,750$71.90$485,325.00View SEC Filing  
2/1/2016Stephen D ChubbDirectorSell2,000$74.76$149,520.00View SEC Filing  
12/17/2015George MassaroDirectorSell7,740$80.00$619,200.00View SEC Filing  
12/17/2015Thomas F. AckermaninsiderSell10,000$80.00$800,000.00View SEC Filing  
11/19/2015Thomas F. AckermaninsiderSell10,000$75.00$750,000.00View SEC Filing  
11/4/2015Thomas F. AckermaninsiderSell21,612$70.01$1,513,056.12View SEC Filing  
11/2/2015Stephen D ChubbDirectorSell2,000$66.57$133,140.00View SEC Filing  
8/17/2015Thomas F AckermanInsiderSell5,000$75.53$377,650.00View SEC Filing  
5/15/2015Thomas F AckermanCFOSell3,900$70.51$274,989.00View SEC Filing  
5/7/2015George MassaroDirectorSell1,360$70.21$95,485.60View SEC Filing  
3/3/2015Stephen D ChubbDirectorSell2,000$75.52$151,040.00View SEC Filing  
3/2/2015Deborah Turner KochevarDirectorSell2,600$76.59$199,134.00View SEC Filing  
3/2/2015James C FosterCEOSell2,036$76.93$156,629.48View SEC Filing  
3/2/2015Nancy GillettVPSell4,379$76.72$335,956.88View SEC Filing  
2/27/2015Nancy GillettVPSell2,772$76.95$213,305.40View SEC Filing  
2/25/2015James C FosterCEOSell4,621$75.96$351,011.16View SEC Filing  
2/25/2015Nancy GillettVPSell5,015$76.12$381,741.80View SEC Filing  
2/24/2015James C FosterCEOSell4,800$75.70$363,360.00View SEC Filing  
2/24/2015Jorg GellerVPSell12,061$76.17$918,686.37View SEC Filing  
2/23/2015James C FosterCEOSell8,423$76.56$644,864.88View SEC Filing  
2/23/2015Jorg GellerVPSell7,041$76.59$539,270.19View SEC Filing  
2/20/2015George M Milne JrDirectorSell6,000$75.87$455,220.00View SEC Filing  
2/19/2015James C FosterCEOSell9,671$75.00$725,325.00View SEC Filing  
2/18/2015Stephen D ChubbDirectorSell5,011$73.97$370,663.67View SEC Filing  
2/17/2015Jorg GellerVPSell14,430$73.54$1,061,182.20View SEC Filing  
2/17/2015Thomas F AckermanCFOSell4,400$73.50$323,400.00View SEC Filing  
2/13/2015Davide MolhoVPSell19,075$74.00$1,411,550.00View SEC Filing  
2/12/2015Jorg GellerVPSell8,458$73.68$623,185.44View SEC Filing  
1/26/2015Thomas F AckermanCFOSell10,000$70.00$700,000.00View SEC Filing  
1/8/2015David P JohstVPSell4,737$67.00$317,379.00View SEC Filing  
1/7/2015David P JohstVPSell26,100$65.00$1,696,500.00View SEC Filing  
12/1/2014Stephen D ChubbDirectorSell2,000$64.44$128,880.00View SEC Filing  
11/28/2014David P JohstVPSell6,982$65.34$456,203.88View SEC Filing  
11/17/2014Thomas F AckermanCFOSell10,000$63.70$637,000.00View SEC Filing  
11/14/2014Jorg GellerVPSell5,610$63.57$356,627.70View SEC Filing  
11/6/2014C Richard ReeseDirectorSell5,849$63.39$370,768.11View SEC Filing  
11/4/2014John J CrowleyCAOSell1,000$64.00$64,000.00View SEC Filing  
11/3/2014Davide MolhoVPSell16,402$64.54$1,058,585.08View SEC Filing  
11/3/2014George MassaroDirectorSell16,710$65.00$1,086,150.00View SEC Filing  
11/3/2014Thomas F AckermanCFOSell36,100$65.00$2,346,500.00View SEC Filing  
10/30/2014Nancy GillettVPSell1,069$65.00$69,485.00View SEC Filing  
10/28/2014David P JohstVPSell74,780$64.00$4,785,920.00View SEC Filing  
10/3/2014James C FosterCEOSell136,647$62.00$8,472,114.00View SEC Filing  
9/29/2014Thomas F AckermanCFOSell5,000$60.00$300,000.00View SEC Filing  
9/4/2014Davide MolhoVPSell4,900$61.34$300,566.00View SEC Filing  
9/2/2014Stephen D ChubbDirectorSell2,000$59.18$118,360.00View SEC Filing  
8/26/2014George MassaroDirectorSell10,440$60.00$626,400.00View SEC Filing  
8/18/2014Thomas F AckermanCFOSell23,156$59.25$1,371,993.00View SEC Filing  
8/12/2014Richard F WallmanDirectorSell3,240$58.20$188,568.00View SEC Filing  
6/2/2014Stephen D ChubbDirectorSell2,000$52.93$105,860.00View SEC Filing  
5/22/2014Deborah Turner KochevarDirectorSell3,100$53.30$165,230.00View SEC Filing  
5/8/2014George MassaroDirectorSell1,620$52.70$85,374.00View SEC Filing  
5/5/2014Thomas AckermanCFOSell5,430$50.76$275,626.80View SEC Filing  
3/7/2014Nancy GillettVPSell10,110$58.36$590,019.60View SEC Filing  
3/4/2014Nancy GillettVPSell13,650$58.98$805,077.00View SEC Filing  
3/3/2014Stephen ChubbDirectorSell2,000$58.70$117,400.00View SEC Filing  
2/28/2014Jorg GellerVPSell7,486$59.41$444,743.26View SEC Filing  
2/27/2014Nancy GillettVPSell4,000$60.00$240,000.00View SEC Filing  
2/25/2014Jorg GellerVPSell3,188$58.49$186,466.12View SEC Filing  
2/20/2014Nancy GillettVPSell4,000$58.96$235,840.00View SEC Filing  
2/19/2014Stephen ChubbDirectorSell5,198$58.35$303,303.30View SEC Filing  
2/18/2014Thomas AckermanCFOSell14,000$58.05$812,700.00View SEC Filing  
1/13/2014David JohstVPSell19,750$58.00$1,145,500.00View SEC Filing  
1/7/2014George MassaroDirectorSell5,750$54.00$310,500.00View SEC Filing  
12/20/2013Thomas AckermanCFOSell5,000$52.72$263,600.00View SEC Filing  
12/4/2013Jorg GellerVPSell7,200$51.93$373,896.00View SEC Filing  
12/2/2013Stephen ChubbDirectorSell2,000$51.92$103,840.00View SEC Filing  
9/16/2013George MassaroDirectorSell5,958$47.38$282,290.04View SEC Filing  
9/9/2013James C FosterCEOSell174,479$47.00$8,200,513.00View SEC Filing  
9/4/2013Thomas F AckermanCFOSell6,100$46.13$281,393.00View SEC Filing  
9/3/2013Stephen ChubbDirectorSell2,000$46.49$92,980.00View SEC Filing  
8/29/2013James FosterCEOSell40,983$47.00$1,926,201.00View SEC Filing  
8/22/2013Davide MolhoVPSell6,500$47.93$311,545.00View SEC Filing  
8/20/2013Stephen ChubbDirectorSell4,000$47.46$189,840.00View SEC Filing  
8/5/2013Jorg GellerVPSell3,025$46.38$140,299.50View SEC Filing  
8/5/2013Richard WallmanDirectorSell1,500$45.95$68,925.00View SEC Filing  
8/2/2013Davide MolhoVPSell4,100$45.89$188,149.00View SEC Filing  
8/2/2013Deborah Turner KochevarDirectorSell4,447$46.02$204,650.94View SEC Filing  
8/2/2013Thomas AckermanCFOSell26,250$46.03$1,208,287.50View SEC Filing  
6/3/2013Thomas F AckermanCFOSell4,000$42.40$169,600.00View SEC Filing  
5/14/2013James C FosterCEOSell113,810$45.00$5,121,450.00View SEC Filing  
5/10/2013George MassaroDirectorSell2,020$44.09$89,061.80View SEC Filing  
3/13/2013David P JohstVPSell17,038$45.00$766,710.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Charles River Laboratories International (NYSE:CRL)
DateHeadline
News IconIt's Earnings Time: What to Do with Charles River Laboratories International, Inc. (NYSE:CRL) Stock - The Voice Registrar (NYSE:CRL)
voiceregistrar.com - August 27 at 4:12 PM
stocksdaily.net logoCharles River Laboratories International, Inc. (NYSE:CRL) Paying ... - Stocks Daily (NYSE:CRL)
www.stocksdaily.net - August 25 at 4:29 PM
moodys.com logoMoody's Upgrades Two, Affirms Three and Downgrades One Class of MLCFC 2006-2 (NYSE:CRL)
www.moodys.com - August 18 at 9:39 PM
investornewswire.com logoWill Charles River Laboratories International, Inc. (NYSE:CRL) Hit $100 Price Target? - Investor Newswire (NYSE:CRL)
www.investornewswire.com - August 17 at 9:48 PM
News IconCharles River Laboratories announces partnership with the Milner Therapeutics Institute and Consortium - Drug Target Review (NYSE:CRL)
www.drugtargetreview.com - August 11 at 10:14 PM
finance.yahoo.com logoWill This Clinical Researcher Become Next Breakout Medical Stock? (NYSE:CRL)
finance.yahoo.com - August 11 at 4:32 PM
finance.yahoo.com logoCHARLES RIVER LABORATORIES INTERNATIONAL INC Financials (NYSE:CRL)
finance.yahoo.com - August 10 at 4:29 PM
capitalcube.com logoETF’s with exposure to Charles River Laboratories International, Inc. : August 10, 2016 (NYSE:CRL)
www.capitalcube.com - August 10 at 4:29 PM
capitalcube.com logoCharles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : August 9, 2016 (NYSE:CRL)
www.capitalcube.com - August 9 at 10:50 AM
businesswire.com logoCharles River Laboratories Announces Partnership with the Milner Therapeutics Institute and Consortium - Business Wire (press release) (NYSE:CRL)
www.businesswire.com - August 8 at 9:47 PM
capitalcube.com logoCharles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NYSE:CRL)
www.capitalcube.com - August 8 at 4:29 PM
streetreport.co logoCharles River Laboratories International Inc (NYSE:CRL) Announced Q2 Profit of $35.2 Million - Street Report (NYSE:CRL)
www.streetreport.co - August 5 at 11:13 AM
seekingalpha.com logoCharles River Laboratories International's (CRL) CEO Jim Foster on Q2 2016 Results - Earnings Call Transcript (NYSE:CRL)
seekingalpha.com - August 4 at 4:35 PM
investornewswire.com logoStrong Sell Calls For Charles River Laboratories International, Inc. (NYSE:CRL) At 1 - Investor Newswire (NYSE:CRL)
www.investornewswire.com - August 4 at 10:50 AM
News IconCharles River Laboratories International Inc. (NYSE:CRL) Earnings Beat Consensus Estimates - BNB Daily (blog) (NYSE:CRL)
www.baseball-news-blog.com - August 3 at 10:03 PM
finance.yahoo.com logoEdited Transcript of CRL earnings conference call or presentation 3-Aug-16 12:30pm GMT (NYSE:CRL)
finance.yahoo.com - August 3 at 10:03 PM
nasdaq.com logoCharles River Q2 Results Top Estimates; Lifts FY16 Adj. EPS, Revenue Growth View (NYSE:CRL)
www.nasdaq.com - August 3 at 10:38 AM
tmcnet.com logoCharles River Laboratories Announces Second-Quarter 2016 Results from Continuing Operations (NYSE:CRL)
www.tmcnet.com - August 3 at 10:38 AM
twst.com logoCharles River Laboratories International Inc.: Charles River Laboratories Announces Second-Quarter 2016 Results from Continuing Operations (NYSE:CRL)
www.twst.com - August 3 at 10:38 AM
rttnews.com logoCharles River Laboratories International Inc. Profit Climbs 25% In Q2 (NYSE:CRL)
www.rttnews.com - August 3 at 10:38 AM
sg.finance.yahoo.com logoCharles River beats Street 2Q forecasts (NYSE:CRL)
sg.finance.yahoo.com - August 3 at 10:38 AM
biz.yahoo.com logoCHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Finan (NYSE:CRL)
biz.yahoo.com - August 3 at 10:38 AM
biz.yahoo.com logoCharles River Laboratories International Inc Earnings Call scheduled for 8:30 am ET today (NYSE:CRL)
biz.yahoo.com - August 3 at 10:38 AM
investornewswire.com logoCan Shares Of Charles River Laboratories International, Inc. (NYSE:CRL) Hit $97? - Investor Newswire (NYSE:CRL)
www.investornewswire.com - July 27 at 10:05 PM
nasdaq.com logoCharles River Laboratories International Reaches Analyst Target Price - Nasdaq (NYSE:CRL)
www.nasdaq.com - July 27 at 10:05 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Charles River Laboratories International, Inc. (NYSE:CRL) - TGP (NYSE:CRL)
telanaganapress.com - July 22 at 10:50 AM
tradecalls.org logoFox Run Management L.l.c. adds Charles River Laboratories (CRL) to its portfolio - Trade Calls (NYSE:CRL)
www.tradecalls.org - July 22 at 10:50 AM
News IconShares Positive Over the Past Month: Charles River Laboratories International, Inc. (NYSE:CRL) - TGP (NYSE:CRL)
telanaganapress.com - July 21 at 5:58 AM
News IconAre Analysts Bullish Charles River Laboratories Intl. Inc (NYSE:CRL) After Last Week? - Press Telegraph (NYSE:CRL)
presstelegraph.com - July 21 at 5:58 AM
News IconQuick View of Earnings: Charles River Laboratories International, Inc. (NYSE:CRL), Catalent, Inc. (NYSE:CTLT ... - Engelwood Daily (NYSE:CRL)
www.engelwooddaily.com - July 21 at 5:58 AM
News IconStock Strength in Focus for Charles River Laboratories International, Inc. (NYSE:CRL) - Press Telegraph (NYSE:CRL)
presstelegraph.com - July 21 at 5:58 AM
investornewswire.com logoIs $97 Price Target Attainable For Charles River Laboratories International, Inc. (NYSE:CRL)? - Investor Newswire (NYSE:CRL)
www.investornewswire.com - July 21 at 5:58 AM
fiscalstandard.com logoCharles River Laboratories International, Inc. (NYSE:CRL) Broker Price Targets For The Coming Week - Fiscal Standard (NYSE:CRL)
www.fiscalstandard.com - July 19 at 9:45 PM
News IconLong Term Value Play: Charles River Laboratories International, Inc. (NYSE:CRL) - TGP (NYSE:CRL)
telanaganapress.com - July 19 at 9:45 PM
News IconCharles River Laboratories International, Inc. (NYSE:CRL): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NYSE:CRL)
www.engelwooddaily.com - July 19 at 9:45 PM
News IconReview on Stock Valuation for: Charles River Laboratories International, Inc. (NYSE:CRL) - TGP (NYSE:CRL)
telanaganapress.com - July 18 at 4:36 PM
News IconShare Performance Summary for: Charles River Laboratories International, Inc. (NYSE:CRL) - Press Telegraph (NYSE:CRL)
presstelegraph.com - July 18 at 4:36 PM
News IconCrowd Rating and Earnings Recap for Charles River Laboratories International, Inc. (NYSE:CRL) - Telanagana Press (NYSE:CRL)
telanaganapress.com - July 15 at 8:28 PM
News IconConsensus Target and Stock Rating Report: Charles River Laboratories International, Inc. (NYSE:CRL) - Telanagana Press (NYSE:CRL)
telanaganapress.com - July 15 at 8:28 PM
ftsenews.co.uk logoCharles River Laboratories International, Inc. (NYSE:CRL) Updated Price Targets - FTSE News (NYSE:CRL)
www.ftsenews.co.uk - July 15 at 8:28 PM
stocksdaily.net logoCharles River Laboratories International, Inc. (NYSE:CRL) Quarterly Dividend Was $-1.357 Millions - Stocks Daily (NYSE:CRL)
www.stocksdaily.net - July 13 at 4:30 PM
News IconAnalyst Target and Average Rating Watch: Charles River Laboratories International, Inc. (NYSE:CRL) - Press Telegraph (NYSE:CRL)
presstelegraph.com - July 12 at 9:49 PM
News IconCharles River Laboratories International, Inc. (NYSE:CRL) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NYSE:CRL)
www.engelwooddaily.com - July 12 at 9:49 PM
News IconShare Strength Review for Charles River Laboratories International, Inc. (NYSE:CRL) - Press Telegraph (NYSE:CRL)
presstelegraph.com - July 12 at 9:49 PM
news.cmlviz.com logoCharles River Laboratories International Inc Realized Volatility Hits a Dropping Level - CML News (NYSE:CRL)
news.cmlviz.com - July 12 at 9:49 PM
News IconShares Positive on the Year: Charles River Laboratories International, Inc. (NYSE:CRL) - Telanagana Press (NYSE:CRL)
telanaganapress.com - July 12 at 8:43 AM
finance.yahoo.com logoCharles River Laboratories Schedules Second-Quarter 2016 Earnings Release and Conference Call - Yahoo Finance (NYSE:CRL)
finance.yahoo.com - July 12 at 8:43 AM
publicnow.com logoCharles River Laboratories Schedules Second-Quarter 2016 Earnings Release and Conference Call (NYSE:CRL)
www.publicnow.com - July 11 at 4:53 PM
News IconStock Rating Watch and Earnings Insight for Charles River Laboratories International, Inc. (NYSE:CRL) - Press Telegraph (NYSE:CRL)
presstelegraph.com - July 11 at 9:11 AM
News IconStock Performance Rundown on: Charles River Laboratories International, Inc. (NYSE:CRL) - Press Telegraph (NYSE:CRL)
presstelegraph.com - July 10 at 4:14 PM

Social

Charles River Laboratories International (NYSE:CRL) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff